Recent advances in immunotherapy — an approach that mobilizes the immune system to fight disease — have revolutionized treatments for certain cancers. We’re determined to make sure chordoma patients benefit from these discoveries, too.
Fundamentally, that requires understanding how chordoma interacts with the immune system, and using that knowledge to identify and test relevant treatments.
To address these needs, we and our partners at the Cancer Research Institute (CRI) — the leading funder of cancer immunotherapy research — have identified a new, high priority chordoma immunotherapy research project proposed by a team of renowned physicians and scientists at Northwestern Medicine, led by Dr. Jean-Paul Wolinsky.
Together, they will:
- Uncover new insights about the immune landscape of chordoma
- Test promising immunotherapies in chordoma mouse models
- Translate the findings to immunotherapy clinical trials as quickly as possible
With your help, this work can soon be underway. And because CRI is matching contributions from the chordoma community, every donation will go twice as far.
|
|
A fitting conclusion to our ALL IN campaign
This project is part of an ambitious Immunotherapy Initiative we’ve launched in recent years, a key pillar of our ongoing $16M ALL IN campaign. Thanks to the generosity of this community we’re now at more than 99% of that goal, and the funding needed to enable this new immunotherapy project will bring us across the finish line!
Thus, in joining with us to make this important immunotherapy project possible, you’ll also be among the final people who bring the ALL IN campaign to a successful conclusion — and help realize the collective achievement of more than 5,700 other supporters.
|
|
|
|
|